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Abstract
The cellular prion protein, PrPC, is a glycosylphosphatidylinositol anchored-membrane gly-
coprotein expressed most abundantly in neuronal and to a lesser extent in non-neuronal
cells. Its conformational conversion into the amyloidogenic isoform in neurons is a key path-
ogenic event in prion diseases, including Creutzfeldt-Jakob disease in humans and scrapie
and bovine spongiform encephalopathy in animals. However, the normal functions of PrPC
remain largely unknown, particularly in non-neuronal cells. Here we show that stimulation of
PrPC with anti-PrP monoclonal antibodies (mAbs) protected mice from lethal infection with
influenza A viruses (IAVs), with abundant accumulation of anti-inflammatory M2 macro-
phages with activated Src family kinases (SFKs) in infected lungs. A SFK inhibitor dasatinib
inhibited M2 macrophage accumulation in IAV-infected lungs after treatment with anti-PrP
mAbs and abolished the anti-PrP mAb-induced protective activity against lethal influenza
infection in mice. We also show that stimulation of PrPC with anti-PrP mAbs induced M2
polarization in peritoneal macrophages through SFK activation in vitro and in vivo. These
results indicate that PrPC could activate SFK in macrophages and induce macrophage
polarization to an anti-inflammatory M2 phenotype after stimulation with anti-PrP mAbs,
thereby eliciting protective activity against lethal infection with IAVs in mice after treatment
with anti-PrP mAbs. These results also highlight PrPC as a novel therapeutic target for IAV
infection.
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Author summary
We show here that stimulation of PrPC with anti-PrP mAbs protected mice from lethal
infection with IAVs by stimulating macrophage polarization to an anti-inflammatory M2
phenotype through activation of SFKs in infected lungs. IAVs are causative agents for sea-
sonal epidemic outbreaks of influenza, and often cause high morbidity and mortality in
infected people, particularly in the young and elderly and those with underlying chronic
diseases. It has also been reported that highly pathogenic avian IAVs have the potential to
infect humans and cause high morbidity and mortality in infected individuals. The other
problem with IAV infections is that new IAV strains, which are resistant to currently
available anti-influenza agents such as neuraminidase inhibitors, have been emerging in
human populations. Our current results showing that targeting PrPC with anti-PrP mAbs
protected against lethal infection with IAVs in mice give rise to the possibility that PrPC-
targeting therapeutics might be beneficial in influenza infection. Moreover, since PrPC is a
host molecule, PrPC-targeting drugs might not induce drug-resistant IAVs. Thus, PrPC
might be a novel target molecule for therapeutic development for IAV infection, although
further studies are needed.
Introduction
The normal cellular isoform of prion protein, designated PrPC, is a membrane glycoprotein
tethered to the outer cell membrane via a glycosylphosphatidylinositol (GPI) anchor moiety
and expressed most abundantly in the brain, particularly by neurons, and to a lesser extent in
non-neuronal tissues such as heart, lung, and spleen [1–3]. Conformational conversion of
PrPC into the amyloidogenic isoform, PrPSc, in the brain is a key pathogenic event in prion dis-
eases, a group of neurodegenerative disorders, which include Creutzfeldt-Jakob disease in
humans and scrapie and bovine spongiform encephalopathy in animals [1]. Mice devoid of
PrPC (Prnp0/0) have been shown to be vulnerable to ischemic injury in the brain, heart and kid-
ney, with enhanced apoptosis in the injured tissues [4–8], suggesting that PrPC could have a
cellular protective function in these tissues. It has also been previously shown that lung epithe-
lial cells in Prnp0/0 mice were highly vulnerable to apoptotic cell death after infection with
influenza A viruses (IAVs), suggesting that PrPC could have a protective role for lung epithelial
cells [3,9].
IAVs are enveloped, negative sense, single-stranded RNA viruses causing seasonal epidemic
outbreaks of the acute upper respiratory disease influenza [10]. Severe influenza infections are
often lethal, causing high morbidity and mortality in infected people, particularly in the young
and elderly and those with underlying chronic diseases in lung or cardiovascular systems [10].
Currently available main anti-influenza agents are viral protein-targeting agents such as neur-
aminidase inhibitors. However, emergence of influenza viruses that are resistant to these
agents has been reported and may become a serious problem if these drug-resistant IAVs
spread in human populations [11–13]. It has also been shown that highly pathogenic avian
IAVs of the H5N1 and H7N9 subtypes have the potential to infect humans, causing high mor-
bidity and mortality in infected individuals, raising another concern about the pandemic
potential of these avian viruses in human populations [14–16]. Therefore, identification of
new target molecules for anti-influenza agents is urgently awaited.
In this study, we show a novel function of PrPC to induce anti-inflammatory M2 macro-
phage polarization through activation of Src family kinases (SFKs), and that anti-PrP mono-
clonal antibodies (mAbs) stimulated the novel activity of PrPC inducing M2 macrophages and
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thereby protected mice from lethal infection with IAVs. These results suggest that PrPC could
be a novel therapeutic target for influenza infection by promoting M2 macrophage
polarization.
Results
38–2 anti-PrP mAb provides protection against lethal IAV infection in
mice
To examine if PrPC could be stimulated by anti-PrP Abs and provide beneficial effects in IAV
infection, various doses of 38–2 anti-PrP IgG mAb, which recognizes residues 41–45 of mouse
PrPC [17], was intraperitoneally administered to C57BL/6 wild-type (WT) mice 1 day before
intranasal infection with influenza virus strain A/Puerto Rico/8/34 (H1N1) (hereafter referred
to as IAV/PR8) with 200 infectious units (IFU). The 38–2 hybridoma was established by fusion
of myeloma cells with splenocytes from Prnp0/0 mice immunized with recombinant mouse
PrP [17]. Approximately 90% of control mice, which received vehicle buffer alone, died by 14
days post infection (dpi) (Fig 1A and S1 Fig). However, 38–2 mAb markedly reduced the
mortality of infected mice in a dose-dependent manner (Fig 1A and S1 Fig). Weight loss was
also mitigated in 38–2 mAb-treated, IAV/PR8-infected mice compared to control mice (Fig
1A and S1 Fig). These results indicate that targeting of PrPC with 38–2 mAb could confer pro-
tection against lethal IAV infection in mice. We then investigated the Fab fragment of 38–2
mAb for its protective activity against lethal IAV infection, by intraperitoneally injecting the
38–2 Fab fragment (1 mg/mouse) into WT mice 1 day before infection with 200 IFU of IAV/
PR8. The 38–2 Fab fragment also significantly reduced the mortality of infected WT mice
compared to control Fab fragment (Fig 1B), indicating that the 38–2 mAb-mediated protec-
tive activity of PrPC against lethal IAV infection does not depend on cross-linking of PrPC or
any Fc-dependent Ab functions.
To confirm that the protective activity of 38–2 mAb against lethal IAV infection is mediated
through targeting PrPC, we similarly injected 38–2 mAb (1 mg/mouse) into Prnp0/0 and WT
mice 1 day before infection with 100 IFU of IAV/PR8. Purified unimmunized mouse poly-
clonal IgG was also administered into WT mice as a control. Since Prnp0/0 mice had been
reported to be highly susceptible to IAV/PR8 infection [3], we used lower doses (100 IFU) of
IAV/PR8 in this experiment. 38–2 mAb consistently reduced the mortality and weight loss of
infected WT mice (Fig 1C). However, the mortality and weight loss of infected Prnp0/0 mice
was not affected by 38–2 mAb (Fig 1C). These results confirm that targeting of PrPC is essen-
tial for 38–2 mAb to elicit its protective activity against lethal IAV infection.
38–2 mAb suppresses IAV-infected lung pathologies
To investigate the effects of 38–2 mAb on IAV-infected lung pathologies, we microscopically
examined the lungs of control IgG- and 38–2 mAb-treated WT mice uninfected and at 3 and 5
dpi with IAV/PR8 (200 IFU). No solid lesions with infiltration of inflammatory cells were
detected in the parenchymal and bronchiolar areas of uninfected lungs (Fig 2A). However,
inflammatory cells had infiltrated these areas of control IgG- and 38–2 mAb-treated, IAV/
PR8-infected lungs, particularly markedly at 5 dpi, with much milder infiltration of inflamma-
tory cells in 38–2 mAb-treated, IAV/PR8-infected lungs than in control lungs at 3 and 5 dpi
(Fig 2A). Neither hyaline membrane formation nor hemorrhage was observed in these lungs
(Fig 2A). Wet weight of 38–2 mAb-treated, IAV/PR8-infected lungs was significantly lighter
than that of control lungs (S2 Fig), suggesting lower exudates in the former lungs than in the
latter. Atelectatic lung areas were also smaller in the former lungs than in the latter (Fig 2B).
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Fig 1. 38–2 mAb provokes protection against lethal infection with IAV/PR8 in mice. (A) The survival rate (%,
upper panel) and body weight loss (%, lower panel) of WT mice intraperitoneally administered with either the buffer
alone (0 mg/mouse) or 38–2 mAb (1mg/mouse) 1 day before intranasal infection with 200 IFU of IAV/PR8. Error
bars, standard deviations (SD). (B) Survival rate (%, upper panel) and body weight loss (%, lower panel) of WT mice
intraperitoneally administered with control IgG Fab and 38–2 Fab fragments 1 day before intranasal infection with 200
IFU of IAV/PR8. Error bars, SD. (C) Survival rate (%, upper panel) and body weight loss (%, lower panel) of WT and
Prnp0/0 mice intraperitoneally administered with 38–2 mAb and control IgG 1 day before intranasal infection with 100
IFU of IAV/PR8. Error bars, SD.�, p<0.05; ��, p<0.01.
https://doi.org/10.1371/journal.ppat.1008823.g001
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Levels of inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-
α), and interferon-γ (IFN-γ) were also lower in 38–2 mAb-treated, IAV/PR8-infected lungs
than in control lungs (Fig 2C). We also assessed lung damage in 38–2 mAb-treated, IAV/
PR8-infected mice. Apoptotic marker cleaved caspase 3 fragments were lower in 38–2 mAb-
treated, IAV/PR8-infected lungs than in control lungs (Fig 2D, 2E and S3 Fig). Terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay also showed
lower TUNEL-positive cells in 38–2 mAb-treated, IAV/PR8-infected lungs than in control
lungs (S4 Fig). Protein levels of the alveolar type 1 (AT1) epithelial cell marker podoplanin
was unchanged during IAV infection (Fig 2D, 2E and S3 Fig). This is consistent with AT1 epi-
thelial cells in C57BL/6 mice being resistant to IAV infection [18]. In contrast, pulmonary sur-
factant protein C (SP-C) and Clara cell 10-kDa protein (CC10), which are specific markers for
AT2 and Clara epithelial cells, respectively, remained higher in 38–2 mAb-treated, IAV/
PR8-infected lungs than in control lungs (Fig 2D, 2E and S3 Fig). This suggests that AT2 and
Clara cells are less damaged in 38–2 mAb-treated, IAV/PR8-infected lungs than in control
lungs. Virus titers and levels of viral proteins including PB1, NS1 and M2 were also lower in
38–2 mAb-treated, IAV/PR8-infected lungs than in control lungs (Fig 2F and 2G). Viral pro-
tein NP-positive areas were also limited in the former lungs compared to the latter (Fig 2H).
The NP-positive cells were observed in the airway and parenchymal areas of both IgG- or 38–2
mAb-treated, IAV/PR8-infected lungs at 3 and 5 dpi. However, they were gradually increased
in the airway and parenchymal areas of 38–2 mAb-treated lungs, but rapidly in control lungs
(Fig 2I and 2J). These results suggest that 38–2 mAb also could affect the susceptibility of lung
epithelial cells to IAV/PR8 without altering the cell tropism of IAV/PR8 in the lung. Taken
together, these results indicate that 38–2 mAb could suppress IAV infection-induced lung
pathologies, including inflammatory cell infiltration, inflammatory cytokine production, epi-
thelial cell damage, and IAV production.
38–2 mAb does not activate SOD1 in IAV-infected lungs
It has been reported that PrPC could provide protection against IAV infection in mice, by
reducing reactive oxygen species (ROS) through activation of Cu/Zn-dependent superoxide
dismutase (SOD1) in infected lungs [3]. To address if SOD1 activity could be involved in the
38–2 mAb-induced protective activity of PrPC against lethal IAV infection, we investigated
whether 38–2 mAb could induce activation of SOD1 in IAV-infected lungs. ROS levels were
slightly lower in 38–2 mAb-treated lungs than in control lungs at 3 dpi with IAV/PR8 (200
IFU) (Fig 3A). However, enzymatic activity of SOD1 was similarly elevated in both lungs (Fig
3B). Protein levels of SOD1 were also unchanged in both lungs (Fig 3C). These results suggest
Fig 2. 38–2 mAb suppresses lung pathologies of IAV-infected mice. (A) Hemotoxylin-Eosin-stained lungs from control IgG- and 38–2 mAb-treated mice
uninfected and at 3 and 5 dpi with 200 IFU of IAV/PR8. Bar, 1 mm. Atelectatic area (%) (B) and levels of pro-inflammatory cytokines (C) in the lungs from
control IgG- and 38–2 mAb-treated mice uninfected and at 3 and 5 dpi with 200 IFU of IAV/PR8 (n = 3 in each group). Un, uninfected. (D) Western blotting
for the AT1 cell marker podoplanin, the AT2 cell marker SP-C, the Clara cell marker CC10, pro-caspase 3, and the cleaved caspase 3 in lungs from control IgG-
and 38–2 mAb-treated mice uninfected and at 3 and 5 dpi with 200 IFU of IAV/PR8. Actb, β-actin. (E) The percent density of indicated proteins against the
densities of the corresponding proteins in IgG-treated, uninfected lungs after being normalized by the densities of β-actin (n = 3 in each group). Un,
uninfected. (F) Virus titers in the lungs from control IgG- and 38–2 mAb-treated mice at 3 and 5 dpi with 200 IFU of IAV/PR8 (n = 3 in each group). (G)
Western blotting for the viral proteins, PB1, NS1, and M2 in the lungs from control IgG- and 38–2 mAb-treated mice uninfected and at 3 and 5 dpi with 200
IFU of IAV/PR8. Actb, β-actin. (H) Immunofluorescent staining for the viral protein NP in the lungs from control IgG- and 38–2 mAb-treated mice
uninfected and at 3 and 5 dpi with 200 IFU of IAV/PR8. Bar, 1 mm. (I) Injury score (%) of NP-positive large airways in (H). Score 0, intact epithelial cells in the
airway without NP-positive cells; score 1, intact epithelial cells in the airway with<50% NP-positive cells; score 2, intact epithelial cells in the airway with>50%
NP-positive cells; score 4,<50% epithelial cell injuries in the airway with NP-positive cells; score 5,>50% epithelial cell injuries in the airway with NP-positive
cells. n = 3 slices × 3 mice in each group. (J) NP-positive cells/mm2 in the lung parenchymal areas in (H). n = 3 slices × 3 mice in each group.�, p<0.05; ��,
p<0.01.
https://doi.org/10.1371/journal.ppat.1008823.g002
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that the SOD1-mediated anti-oxidative activity of PrPC is not involved in the 38–2 mAb-
induced protective activity of PrPC against lethal IAV infection.
SFK activation is essential for 38–2 mAb to elicit the protective activity
against lethal IAV infection
It has been reported that certain anti-PrP mAbs could activate SFK in neuronal and non-neu-
ronal cells [19–22]. Therefore, to investigate the mechanism by which 38–2 mAb could pro-
voke protection against lethal IAV infection, we first examined if SFK could be activated by
38–2 mAb in IAV-infected lungs, by performing Western blotting for SFK phosphorylation at
tyrosine 416, the activated form of SFK, in the lungs of control IgG- and 38–2 mAb-treated
WT mice at 3 dpi with IAV/PR8 (200 IFU). Phosphorylated SFK (Tyr416) was increased in
38–2 mAb-treated, IAV/PR8-infected lungs, compared to control lungs (Fig 4A), indicating
that 38–2 mAb could activate SFK in IAV-infected lungs. We then investigated the role of SFK
activation in the 38–2 mAb-induced protective activity of PrPC against lethal IAV infection, by
administering 38–2 mAb and control IgG together with the SFK inhibitors dasatinib (DS) and
PP2 into WT mice 1 day before intranasal infection with 200 IFU of IAV/PR8. DS and PP2
had no effects on the mortality of control IgG-treated, IAV/PR8-infected mice (Fig 4B, S5 Fig,
S6A Fig). However, both inhibitors abolished the protective activity of 38–2 mAb against
lethal IAV infection (Fig 4B, S5 Fig, S6A Fig). The survival rate of 38–2 mAb-treated, IAV/
PR8-infected mice was markedly decreased by DS (Fig 4B, S5 Fig) and PP2 (S6A Fig). The
SFK activation and reduction of viral protein M2 and cleaved caspase 3 fragments in 38–2
mAb-treated, IAV/PR8-infected mice were also inhibited by DS (Fig 4C). DS and PP2 inhibit
not only SFKs but also other kinases such as c-Abl and c-Kit. We therefore similarly tested
imatinib, which selectively inhibits c-Abl, platelet-derived growth factor receptor, and c-Kit
[23]. Imatinib failed to inhibit the protective activity of 38–2 mAb against lethal IAV infection
(S6B Fig). These results indicate that 38–2 mAb could activate SFK in IAV-infected lungs, and
that the SFK activation is essential for the 38–2 mAb-induced protective activity of PrPC
against lethal IAV infection.
38–2 mAb induces M2 macrophage polarization through activation of SFK
To further elucidate the mechanism for the 38–2 mAb-induced protective activity of PrPC
against lethal IAV infection, we identified cell-types in which SFK is activated by 38–2 mAb in
Fig 3. SOD1 is not activated by 38–2 mAb in IAV-infected lungs. DCF levels representing ROS levels (A) and SOD
activity (B) in the lungs of IgG- and 38–2 mAb-treated mice uninfected and at 3 dpi with 200 IFU of IAV/PR8 (n = 3
in each group). Un, uninfected. (C) Western blotting for SOD1 in the lungs from control IgG- and 38–2 mAb-treated
mice uninfected and at 3 dpi with 200 IFU of IAV/PR8. Actb, β-actin. The percent density of SOD1 against the
densities of SOD1 in IgG-treated, uninfected lungs after being normalized by the densities of β-actin (n = 3 in each
group). Un, uninfected. �, p<0.05; ��, p<0.01.
https://doi.org/10.1371/journal.ppat.1008823.g003
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IAV/PR8-infected lungs. We used double immunofluorescent staining for phosphorylated
SFK (Tyr416) and various cell markers including macrophage galactose-type C-type lectins 1
and 2 (MGL1/2) for macrophages, CD3 for T lymphocytes, and myeloperoxidase (MPO) for
neutrophils. Signals for phosphorylated SFK (Tyr416) were increased in 38–2 mAb-treated,
IAV/PR8-infected lungs compared to control lungs, and predominantly co-stained with
MGL1/2, but not with CD3 or MPO (Fig 5A), suggesting that 38–2 mAb could activate SFK in
macrophages in IAV-infected lungs.
MGL1/2 is a specific marker for M2 macrophages. We therefore evaluated M1/M2 macro-
phage status in 38–2 mAb-treated, IAV/PR8-infected lungs, by investigating expression levels
of M1 and M2 macrophage-specific genes using real-time reverse transcriptase-polymerase
chain reaction (RT-PCR). Expression levels of the M1-specific genes such as those for IL-6,
TNF-α, IFN-α, IFN-γ, monocyte chemotactic protein-1 (MCP-1) and inducible nitric oxide
synthetase (iNOS) were lower in 38–2 mAb-treated, IAV/PR8-infected lungs than in control
lungs (Fig 5B). Consistently, the IFN-stimulated genes such as those for IFN-induced protein
with tetratricopeptide repeats 1 (IFIT1) and Myxovirus resistance protein A (MxA) also had
reduced expression in 38–2 mAb-treated, IAV/PR8-infected lungs, compared to control lungs
(Fig 5B). In contrast, the M2-specific genes including those for arginase 1 (ARG1), MGL1,
and IL-10 were upregulated in 38–2 mAb-treated, IAV/PR8-infected lungs (Fig 5B). In addi-
tion, DS increased expression of the M1-specific genes and decreased expression of the
M2-specific genes in 38–2 mAb-treated, IAV/PR8-infected lungs (Fig 5B). These results indi-
cate that the 38–2 mAb-induced activation of SFK in macrophages could lead to predomi-
nance of M2 macrophages over M1 macrophages in IAV-infected lungs.
To further clarify the role of 38–2 mAb-induced activation of SFK in macrophage polariza-
tion, we collected peritoneal macrophages and incubated them with 38–2 mAb. We first con-
firmed that peritoneal macrophages express PrPC on Western blotting with 38–2 mAb (Fig
6A). PrPC is a glycoprotein with two glycosylation sites, therefore di-, mono-, and un-glycosy-
lated forms of PrPC are detected as several distinct bands (Fig 6A). 38–2 mAb strongly cross-
reacted with a non-PrP molecule of around 28 kDa in WT and Prnp0/0 peritoneal macrophages
(Fig 6A). Incubation with 38–2 mAb increased phosphorylated SFK (Tyr416) and MGL1/2 in
WT macrophages, but not in Prnp0/0 macrophages (Fig 6B). The SFK activation and MGL1/2
upregulation in 38–2 mAb-treated macrophages were suppressed by DS (Fig 6B). The M2
cytokines, IL-4 and IL-10, but not the M1 cytokines, IFN-γ and TNF-α, were increasingly
released into the medium from 38–2 mAb-treated WT macrophages (Fig 6C). We also directly
injected 38–2 mAb and control IgG into the peritoneal cavity of WT mice (1 mg/mouse) and
collected their peritoneal macrophages 1 and 3 days after injection. Western blotting showed
that WT peritoneal macrophages, but not Prnp0/0 peritoneal macrophages, had increased
phosphorylated SFK (Tyr416) and MGL1/2 after treatment with 38–2 mAb (Fig 6D). The
Fig 4. 38–2 mAb activates SFK in IAV-infected lungs and elicits protective activity against lethal IAV infection.
(A) Western blotting (left panel) for total and phosphorylated SFK in the lungs from control IgG- and 38–2 mAb-
treated mice at 3 dpi with 200 IFU of IAV/PR8. Actb, β-actin. The percent density of total SFK (middle panel) and SFK
phosphorylated at tyrosine 416 (right panel) against the densities of the corresponding proteins in IgG-treated,
infected lungs after being normalized by the densities of β-actin. ��, p<0.01. (B) Survival rate (%, upper panels) and
body weight loss (%, lower panels) of WT mice intraperitoneally administrated with control IgG (left panels) and 38–2
mAb (right panel) together with 20 mg/mouse of DS 1 day before intranasal infection with 200 IFU of IAV/PR8. Error
bars, SD. (C) Western blotting (upper panel) for total SFK, phosphorylated SFK (Tyr416), the cleaved caspase 3, and
the viral protein M2 in the lungs from control IgG/DMSO-, 38–2 mAb/DMSO-, control IgG/DS-, and 38–2 mAb/DS-
treated mice at 3 dpi with 200 IFU of IAV/PR8. Actb, β-actin. Lungs from uninfected, saline/DMSO-treated mice were
used as a control. The percent density (lower panels) of total SFK, phosphorylated SFK (Tyr416), the cleaved caspase 3,
and the viral protein M2 against the densities of the corresponding proteins in uninfected, saline/DMSO-treated lungs
after being normalized by the densities of β-actin. �, p<0.05; ��, p<0.01.
https://doi.org/10.1371/journal.ppat.1008823.g004
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Fig 5. 38–2 mAb activates SFK in M2 macrophage in IAV-infected lungs. (A) Double immunofluorescent staining for phosphorylated SFK (Tyr416)
together with MGL1/2, CD3, and MPO in the lungs from control IgG- and 38–2 mAb-treated mice uninfected and at 3 dpi with 200 IFU of IAV/PR8. Un,
uninfected. Bar, 200 μm. (B) Fold mRNA expression (2-ΔCt) analyzed by real-time RT-PCR for IL-6, TNF-α, IFN-α, INF-γ, MCP-1, iNOS, IFIT1, MxA, ARG1,
MGL1, and IL-10 in the lungs from control IgG/DMSO, control IgG/DS-, 38–2 mAb/DMSO-, and 38–2 mAb/DS-treated mice uninfected and at 3 dpi with
200 IFU of IAV/PR8 (n = 3 in each group). Un, uninfected.�, p<0.05;��, p<0.01.
https://doi.org/10.1371/journal.ppat.1008823.g005
PLOS PATHOGENS PrP in M2 macrophages and influenza
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008823 August 26, 2020 10 / 29
increase in phosphorylated SFK (Tyr416) and MGL1/2 in 38–2 mAb-treated WT mice was
abolished by DS (Fig 6D). We also treated alveolar macrophages collected from the bronchoal-
veolar lavage fluids (BALF) of WT mice with 38–2 mAb, and investigated for expression of the
M1- and M2-specific genes using real-time RT-PCR. The gene expression of M2-specific mol-
ecules, such as MGL1 and IL-10, was increased, but the expression of the M1-specific genes
including those for TNF-α and IFN-γ was decreased, in 38–2 mAb-treated alveolar macro-
phages compared to control IgG-treated alveolar macrophages (S7 Fig). These results suggest
that interaction of 38–2 mAb with PrPC on the surface of macrophages could lead to activation
of SFK in the macrophages and polarize them to M2 macrophages.
Fig 6. 38–2 mAb induces M2 polarization through activation of SFK in peritoneal macrophages. (A) Uncropped,
full picture of Western blotting for PrPC with 38–2 mAb in the lungs (Lg) and peritoneal macrophages (PM) from WT
and Prnp0/0 mice. Actb, β-actin. (B) Western blotting for total SFK, phosphorylated SFK (Tyr416), and MGL1/2 in
peritoneal macrophages from WT and Prnp0/0 mice 3 hrs after treatment with control IgG and 38–2 mAb together
with DS or control DMSO. (C) ELISA for INF-γ, TNF-α, IL-4, and IL-10 in the culture medium from WT peritoneal
macrophages at 0.5, 4, 16, and 24 hours (hrs) after treatment with control IgG and 38–2 mAb.�, p<0.05;�� p<0.01. (D)
Western blotting for total SFK, phosphorylated SFK (Tyr416), and MGL1/2 in peritoneal macrophages (PM) from WT
and Prnp0/0 mice 1 and 3 days after peritoneal injection with control IgG and 38–2 mAb together with control DMSO
and DS.
https://doi.org/10.1371/journal.ppat.1008823.g006
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To investigate which types of SFKs could be activated in macrophages treated with 38–2
mAb, we treated peritoneal macrophages with control IgG and 38–2 mAb, and subjected the
cell lysates to immunoprecipitation with anti-phosphorylated SFK (Tyr416) Ab and then the
precipitates to mass spectrometry. The anti-phosphorylated SFK (Tyr416) Ab most abundantly
precipitated Lyn, with the abundance much higher in 38–2 mAb-treated peritoneal macro-
phages than in control peritoneal macrophages (S8 Fig). To a lesser extent, Hck was also
immunoprecipitated with higher abundance in 38–2 mAb-treated peritoneal macrophages
than control peritoneal macrophages (S8 Fig). Other SFKs including Fyn, Frk, Yes, Fgr, Lck,
and Src were only marginally detectable in the precipitate (S8 Fig). These results indicate that
Lyn and to a lesser extent Hck could be predominantly phosphorylated in peritoneal macro-
phages treated with 38–2 mAb.
38–2 mAb is also therapeutically effective against lethal IAV infection
We also investigated if 38–2 mAb could be therapeutically effective against lethal IAV infec-
tion, by intraperitoneally administering 38–2 mAb into WT mice (1 mg/mouse) 3 or 5 dpi
with 200 IFU of IVA/PR8. Control IgG was similarly injected into WT mice at 3 dpi. Only
20% of control WT mice survived the infection (Fig 7). However, the 3 dpi-treatment with 38–
2 mAb significantly reduced the mortality of infected mice (Fig 7). Weight loss was also
reduced in 38–2 mAb-treated mice compared to control mice (Fig 7). The treatment starting
even at 5 dpi also tended to be slightly but not significantly effective at reducing the mortality
of infected mice (S9 Fig). These results indicate that 38–2 mAb could also be therapeutically
effective against lethal IAV infection.
38–2 mAb also protects against lethal infection with other IAV strains
We further investigated if 38–2 mAb could protect against other IAV strains, by intraperitone-
ally injecting 38–2 mAb (1 mg/mouse) into WT mice 1 day before infection with 600 IFU of
A/Aichi/2/68 (H3N2) (referred to as IAV/Aichi) and 3,000 IFU of A/WSN/33 (H1N1)
(referred to as IAV/WSN). Control IgG was similarly injected into WT mice. Mortality of the
control mice infected with IAV/Aichi and IAV/WSN was about 80% and 50%, respectively
(Fig 8A and 8B). However, 38–2 mAb significantly reduced the mortality to about 30% and
5% in mice infected with IAV/Aichi and IAV/WSN, respectively (Fig 8A and 8B). Weight loss
was also reduced in infected mice by 38–2 mAb (Fig 8A and 8B). These results indicate that
38–2 mAb could confer protection against lethal infection with various IAV strains.
Other anti-PrP mAbs also evoke protection against IAV infection through
a similar mechanism
We also investigated if other anti-PrP mAbs could also evoke protective activity against lethal
IAV infection through the same mechanism as 38–2 mAb. 3S9 and 2H9 anti-PrP IgG mAbs
recognize residues 141–161 of mouse PrPC and a discontinuous epitope included in residues
151–221, respectively [24,25]. 3S9 and 2H9 mAbs also activated SFK and upregulated MGL1/2
in peritoneal macrophages from WT mice but not from Prnp0/0 mice (Fig 9A). The SFK acti-
vation and MGL1/2 upregulation in 3S9 or 2H9 mAb-treated WT macrophages were abol-
ished by DS (Fig 9A). These results indicate that, similarly to 38–2 mAb, 3S9 and 2H9 mAbs
could activate SFK in macrophages and thereby induce M2 macrophage polarization. We then
intraperitoneally administered 3S9 and 2H9 mAbs into mice (1 mg/mouse) 1 day before intra-
nasal infection with 100 or 200 IFU of IAV/PR8. Both mAbs significantly reduced the mortal-
ity of IAV/PR8-infected mice (Fig 9B). These results indicate that 3S9 and 2H9 mAbs could
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also evoke protective activity against lethal IAV infection by inducing M2 macrophage polari-
zation through activating SFK.
Fig 7. Therapeutic effects of 38–2 mAb against IAV infection. The survival rate (%, upper panel) and body weight
loss (%, lower panel) of WT mice intraperitoneally administered with 38–2 mAb 3 days after intranasal infection with
200 IFU of IAV/PR8. Control IgG was similarly injected into WT mice 3 days after infection with 200 IFU of IAV/PR8.
Error bars, SD. �, p<0.05.
https://doi.org/10.1371/journal.ppat.1008823.g007
PLOS PATHOGENS PrP in M2 macrophages and influenza
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008823 August 26, 2020 13 / 29
Anti-PrP mAbs specifically recognize PrPC on the cell surface of
macrophages
To investigate whether 38–2, 3S9, and 2H9 mAbs could specifically recognize PrPC expressed
on the cell surface of macrophages, we first confirmed that all of these mAbs detected PrPC in
the brains and lungs of WT mice by Western blotting (Fig 10A, S10A–S10C Fig). Consistent
with PrPC being expressed as different glycosylated forms, several distinct bands correspond-
ing to the different glycosylated forms of PrPC were detected with these mAbs in WT brains
and lungs, but not in Prnp0/0 brains (Fig 10A, S10A–S10C Fig). PrPC was detected more easily
with 38–2 mAb than with 3S9 and 2H9 mAbs, and the band patterns of PrPC were different
with each of the mAbs (Fig 10A, S10A–S10C Fig). This could be because these mAbs recog-
nize different epitopes. These mAbs also weakly cross-reacted with several other molecules
except for a molecule of around 28 kDa that was strongly cross-reacted with 38–2 mAb in WT
and Prnp0/0 lungs (Fig 10A, S10A–S10C Fig). A similar cross-reactive band was detected with
38–2 mAb in peritoneal macrophages (Fig 6A). It is thus possible that the cross-reactive band
around 28 kDa in WT and Prnp0/0 lungs might be derived from alveolar macrophages.
We then performed FACS analysis with these mAbs. To avoid confusion that might be
caused by expression of endogenous PrPC, we used PrPC-knockout cells, N2aΔPrP cells [26].
The cells were transfected with control vector or pIRES-hrGFP-MoPrP vector, which encodes
mouse PrPC together with the transfection marker humanized Renilla green fluorescent pro-
tein (hrGFP) under the control of an internal ribosomal entry site (IRES) motif. Western blot-
ting with 38–2, 3S9, and 2H9 mAbs showed several distinct bands of PrPC in pIRES-
hrGFP-MoPrP-transfected cells, but not in control vector-transfected cells (Fig 10B). We
Fig 8. Protective activity of 38–2 mAb against other IAV strains. The survival rate (%, upper panels) and body
weight loss (%, lower panels) of WT mice intraperitoneally administered with control IgG and 38–2 mAb 1 day before
intranasal infection with 600 IFU of IAV/Aichi (A) and 3,000 IFU of IAV/WSN (B). Error bars, SD. �, p<0.05; ��,
p<0.01.
https://doi.org/10.1371/journal.ppat.1008823.g008
PLOS PATHOGENS PrP in M2 macrophages and influenza
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008823 August 26, 2020 14 / 29
Fig 9. 3S9 and 2H9 anti-PrP mAbs evokes protection against IAV infection through a similar mechanism. (A)
Western blotting for total SFK, phosphorylated SFK (Tyr416), and MGL1/2 in peritoneal macrophages from WT and
Prnp0/0 mice 3 hrs after treatment with control IgG and 3S9 and 2H9 mAbs together with control DMSO and DS. (B)
Survival rate (%, upper panels) and body weight loss (%, lower panels) of WT mice intraperitoneally administered with
control IgG and 3S9 and 2H9 mAbs 1 day before intranasal infection with 100 (left panels) or 200 IFU (right panels) of
IAV/PR8. Error bars, SD. �, p<0.05; ��, p<0.01; IgG vs 3S9. #,<0.05; IgG vs 2H9.
https://doi.org/10.1371/journal.ppat.1008823.g009
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analyzed hrGFP-positive cells for PrPC expression with these mAbs by FACS. Compared to
control IgG, these mAbs showed a shifted signal in pIRES-hrGFP-MoPrP-transfected cells, but
not in control vector-transfected cells (Fig 10B), indicating that these mAbs could specifically
recognize PrPC expressed on the cell surface of N2aΔPrP cells. We also performed FACS analy-
sis of CD11b-positive peritoneal macrophages from WT and Prnp0/0 mice for PrPC expression
with 38–2, 3S9, and 2H9 mAbs. These mAbs also showed a shifted signal in CD11b-positive
WT macrophages, but not in CD11b-positive Prnp0/0 macrophages (Fig 10C), indicating that
these mAbs could also specifically recognize endogenous PrPC on the cell surface of peritoneal
macrophages.
Discussion
In the present study, we showed that targeting of PrPC with three different anti-PrP mAbs
examined, including 38–2, 3S9 and 2H9, conferred protection against lethal infection with
Fig 10. Anti-PrP mAbs specifically recognize PrPC on the cell surface of macrophages. (A) Western blotting for PrPC in the brains (Br) and lungs (Lg) from
WT and Prnp0/0 mice with 38–2, 3S9, and 2H9 mAbs. (B) FACS analysis (left panel) with control IgG and 38–2, 3S9, and 2H9 mAbs of hrGFP-positive
N2aΔPrP cells 3 days after transfection with control vector and pIRES-hrGFP-MoPrP vector. Western blotting (right panel) with 38–2, 3S9, and 2H9 mAbs of
N2aΔPrP cells transfected with control vector and pIRES-hrGFP-MoPrP vector. (C) FACS analysis with control IgG and 38–2, 3S9, and 2H9 mAbs of CD11b-
positive peritoneal macrophages from WT and Prnp0/0 mice.
https://doi.org/10.1371/journal.ppat.1008823.g010
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IAVs in WT mice. These anti-PrP mAbs mitigated inflammation, inflammatory cytokine pro-
duction, epithelial cell damage and virus production in IAV-infected lungs and eventually
reducing the morbidity and mortality of IAV-infected mice. 38–2 mAb failed to protect Prnp0/
0 mice from lethal infection with IAV/PR8, confirming that targeting of PrPC with anti-PrP
mAbs could elicit the protective activity against IAV infection. We previously showed that,
although Prnp0/0 mice were highly susceptible to IAV infection, they were successfully rescued
from lethal infection with the same IFU of IAV/PR8 as used in WT mice, by treatment with
butylated hydroxyanisole, a radical oxygen species (ROS) scavenger, and allopurinol, the
inhibitor of xanthine oxidase, which is a major ROS-generating enzyme in IAV-infected lungs
[3]. These results indicate that the unsuccessful protection of Prnp0/0 mice by 38–2 mAb could
not be due to the higher sensitivity of Prnp0/0 mice to IAV infection, but due to lack of PrPC in
Prnp0/0 mice. It is thus conceivable that PrPC could be a new therapeutic target for IAV
infection.
It has been previously reported that PrPC could regulate SOD1 activity, thereby reducing
oxidative stress in IAV-infected lungs and providing protection against IAV infection in mice
[3]. However, 38–2 mAb did not increase SOD1 activity in IAV-infected lungs, indicating that
the SOD1-mediated anti-oxidative activity of PrPC is not involved in the anti-PrP mAb-
induced protective activity of PrPC against IAV infection. We showed that Fab fragments of
38–2 mAb reduced the mortality of IAV-infected mice, similarly to its parental 38–2 mAb.
This suggests that the protective activity of the anti-PrP mAbs against IAV infection does not
depend on cross-linking of PrPC or the Fc-dependent Ab functions, such as Ab-dependent
cell-mediated cytotoxicity, Ab-dependent cellular phagocytosis, and Ab-mediated comple-
ment activation leading to complement-dependent cytotoxicity. Consistent with other reports
demonstrating that stimulation of PrPC with certain anti-PrP mAbs activated SFK in cultured
cells [19–22], we observed that SFK was activated in 38–2 mAb-treated, IAV-infected lungs.
Moreover, DS and PP2, which inhibit SFKs as well as c-Abl and c-Kit kinases, but not the c-
Abl and c-Kit kinase-specific inhibitor, imatinib [23], abolished the 38–2 mAb-induced pro-
tective activity of PrPC against IAV infection, decreasing the survival rate of 38–2 mAb-treated,
IAV-infected mice, suggesting that the anti-PrP mAb-induced SFK activation is essential for
the anti-PrP mAb-induced protective activity of PrPC against IAV infection. Administration
with DS alone did not affect the mortality of IAV/PR8-infected mice, suggesting that SFK is
not critically involved in the pathogenesis of IAV infection. Consistent with this, phosphory-
lated SFK (Tyr416) was not increased in the lungs of control IgG-treated, IAV/PR8-infected
mice.
We found that SFK was predominantly activated in M2 macrophages in 38–2 mAb-treated,
IAV-infected lungs, and that DS reduced M2 macrophages and conversely increased M1 mac-
rophages in 38–2 mAb-treated, IAV-infected lungs. We also found that 38–2, 3S9, and 2H9
mAbs activated SFK in peritoneal macrophages from WT mice, but not from Prnp0/0 mice,
and induced M2 polarization in WT macrophages in vitro, and that DS inhibited the anti-PrP
mAbs-induced M2 polarization in WT macrophages. We further showed that 38–2 mAb acti-
vated SFK in peritoneal macrophages and induced M2 macrophage polarization in vivo. FACS
analysis of WT and Prnp0/0 peritoneal macrophages revealed that 38–2, 3S9, and 2H9 mAbs
specifically recognized PrPC on the cell surface of WT peritoneal macrophages. These results
suggest that anti-PrP mAbs could activate SFK through interaction with PrPC on the cell sur-
face of macrophages and induce M2 macrophage polarization. Phosphorylated Lyn and to a
lesser extent phosphorylated Hck were predominantly precipitated with anti-phosphorylated
SFK (Tyr416) Ab in 38–2 mAb-treated peritoneal macrophages, suggesting that these SFKs
might be involved in the anti-PrP mAb-induced M2 polarization in macrophages. These
results also might be consistent with Lyn and Hck being highly expressed in macrophages
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[27]. IL-4 and IL-10, both of which are known to induce M2 macrophage polarization through
the STAT6 pathway [28,29], were abundantly secreted into the culture medium of peritoneal
macrophages after incubation with 38–2 mAb. It is thus possible that IL-4 and IL-10 could be
involved in the anti-PrP mAbs-induced M2 macrophage polarization.
Macrophages are phagocytic cells that play an important role in infectious diseases by trig-
gering innate immunity and regulating various stages of inflammation [28,29]. Based on their
phenotype and function, macrophages can be grouped into two subclasses: pro-inflammatory
M1 and anti-inflammatory M2 macrophages [28,29]. In the early stages of infection, macro-
phages are polarized to a M1 phenotype. They produce inflammatory cytokines including IL-
1, IL-6, and TNF-α, trigger innate immunity, and eventually protect the host from pathogen
colonization. In contrast, M2 macrophages are generated in the late stages of infection, termi-
nating the inflammation and repairing damaged tissues, by releasing anti-inflammatory cyto-
kines such as tumor growth factor-β (TGF-β) and IL-10 and removing damaged cells [28,29].
Several reports indicate that M2 macrophages could be therapeutically beneficial for IAV
infection. Mice intranasally administered with exogenous M2 macrophages or transgenically
expressing granulocyte-macrophage colony-stimulating factor in lung epithelial cells to
increase M2 macrophages were shown to display better clinical scores than control mice after
infection with IAV [30,31]. It is thus likely that the anti-PrP mAb-induced M2 macrophage
generation through SFK activation is the underlying mechanism for the anti-PrP mAb-
induced protective activity of PrPC against IAV infection.
Neuronal loss was reported in mice stereotaxically injected into the hippocampus with D13
and P anti-PrP mAbs, both of which recognize epitopes within residues 95–150 of PrPC [32].
Sonati et al. also reported that anti-PrP mAbs, which recognize the C-terminal globular
domain of PrPC, induced degeneration of cerebellar granule cells in cerebellar organotypic cul-
tured slices and in mice by causing oxidative stress, which was mainly produced by NADPH
oxidase 2 [33]. These results have raised a safety concern for therapeutic application of PrPC-
targeting agents, including anti-PrP mAbs. However, other investigators reported no neuronal
loss in the hippocampus of mice injected with not only D13 and P anti-PrP mAbs but also two
other different anti-PrP mAbs [34]. We also observed that treatment with 38–2 mAb sup-
pressed the caspase 3 activity in IAV-infected lungs, indicating that 38–2 mAb is not toxic to
cells. Further studies are necessary to clarify whether PrPC-targeting agents including anti-PrP
mAbs are safe for therapeutic application.
38–2 and 3S9 mAbs recognize residues 41–45 and 141–161 of PrPC, respectively, and 2H9
mAb reacts with a discontinuous epitope included in residues 151–221 of PrPC [24,25]. Other
anti-PrP mAbs, including SAF32, SAF61, and 3F4, which recognize residues 86–103, 142–160,
and 109–112 of PrPC, respectively, were also shown to induce SFK activation in cultured cells
[19–22]. It is thus likely that various sites, not just a single site, in PrPC could induce SFK acti-
vation after targeting with anti-PrP mAbs. The mechanism by which the binding of anti-PrP
mAbs to extracellular GPI-anchored PrPC leads to activation of intracellular SFK still remains
challenging. It has been reported that the anti-PrP mAbs-mediated activation of SFK in neuro-
nal cells is dependent on caveolin-1 [19]. However, caveolin-1 is an integrated plasma mem-
brane protein forming the cytoplasmic ridges of caveola, with both the N- and C-termini
facing the cytoplasm [35]. It is therefore unlikely that caveolin-1 could directly transduce the
signal from the GPI-anchored extracellular PrPC to the intracellular SFK after stimulation with
anti-PrP mAbs. It has been shown that a small proportion of PrPC molecules on the plasma
membrane could adopt transmembrane forms, with either the N- or C-terminus being
exposed to the cytoplasm [36,37], suggesting that the transmembrane forms of PrPC could
directly interact with and activate SFK in the cytoplasm after stimulation with anti-PrP mAbs.
However, 38–2 mAb reacts with the N-terminal residues of PrPC and 3S9 and 2H9 mAbs
PLOS PATHOGENS PrP in M2 macrophages and influenza
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008823 August 26, 2020 18 / 29
recognize the C-terminal residues, indicating that the transmembrane forms of PrPC are not
responsible for the anti-PrP mAb-induced activation of SFK. Another possibility is that an as
yet unidentified transmembrane molecule(s) could form a link between PrPC and SFK. Anti-
clathrin Ab was reported to partially reduce the anti-PrP mAb-induced activation of SFK [19],
suggesting that clathrin might be a candidate molecule connecting PrPC and SFK. Other can-
didates have been also suggested, including epidermal growth factor receptor and neural cell
adhesion molecule [20,38]. It has been shown that Alzheimer amyloid-β oligomer could bind
to PrPC around the central residues 97–100 and activate SFK in neurons [39], suggesting that
these residues might be involved in the anti-PrP mAb-induced activation of SFK. The polyba-
sic region and the so-called octapeptide region in the N-terminal domain of PrPC have been
suggested to be important to induce intracellular signaling from PrPC [33,40]. However, it is
unknown whether or not these regions could be involved in the anti-PrP mAb-induced activa-
tion of SFK. Identification of a molecule(s) connecting PrPC and SFK and mediating the anti-
PrP mAb-induced activation of SFK and the site involved in the anti-PrP mAb-induced activa-
tion of SFK would be helpful for further understanding of not only the mechanism for the
anti-PrP mAb-induced M2 macrophage polarization, but also the role of the anti-PrP mAb-
induced SFK activation in the normal function of PrPC in neuronal cells.
In short, we showed that targeting of PrPC with anti-PrP mAbs could induce M2 macro-
phage polarization though activation of SFK and thereby confer protection against lethal influ-
enza infection in mice. These results revealed a novel function of PrPC in M2 macrophage
polarization, and suggest that the anti-PrP mAb-induced M2 macrophage-polarizing activity
of PrPC could be a novel therapeutic target for influenza infection. Many lines of evidence are
emerging that induction of M2 macrophages might be beneficial in other non-infectious
chronic inflammatory diseases, including type 2 diabetes, atherosclerosis, and obesity
[28,29,41]. Therefore, it might be interesting to investigate if treatment with anti-PrP mAbs
could be therapeutically beneficial in these diseases. However, careful attention should be paid
to the potential detrimental effects that might be caused by the forced polarization into M2
macrophages by PrPC-targeting agents including anti-PrP mAbs.
Materials and methods
Ethics statement
The Ethics Committee of Animal Care and Experimentation of Tokushima University
approved this study (approval number T30-100 and T2019-81). Mice and chicken embryos
were cared for in accordance with The Guiding Principle for Animal Care and Experimenta-
tion of Tokushima University and with Japanese Law for Animal Welfare and Care. 10-day old
chicken embryos were purchased from Ishii Co., Ltd., Tokushima, Japan.
Animals
C57BL/6 mice were purchased from Japan SLC Inc. (Shizuoka, Japan). Prnp0/0 mice (kindly
provided by Dr. Stanley B. Prusiner) used in this study had been obtained elsewhere by at least
more than 9 time-backcrosses to C57BL/6 with Prnp0/0 mice originally carrying a mixed back-
ground of C57BL/6×129Sv×FVB mice [42,43]. Mice were housed under specific pathogen-free
conditions in cages of 5–6 animals with water and food ad libitum. Cages were provided with
standard softwood bedding. Mice were kept on a standard 12:12 light:dark cycle. The mouse
experiments carried out in this study were reviewed by the Ethics Committees of Animal Care
and Experimentation of Tokushima University every year.
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Antibodies
Anti-podoplanin antibody (Cat. No. D190-3) and anti-β-actin antibody (Cat. No. M177-3)
from MBL (Nagoya, Japan;), anti-SP-C (Cat. No. sc-7706) and anti-CC10 antibodies (Cat. No.
sc-9772) from Santa Cruz Biotechnology (Santa Cruz, CA), anti-pro-caspase 3 (Cat. No.
9662S), anti-cleaved caspase 3 (Cat. No. 9664S), anti-total SFK (Cat. No. 2109S) and anti-phos-
phorylated SFK (Tyr416) antibodies (Cat. No. 2101S) from Cell Signaling (Beverly, MA), anti-
PB1 (Cat. No. GTX125923), anti-NS1 (Cat. No. GTX125990), anti-M2 (Cat. No. GTX125951)
and anti-NP (Cat. No. GTX125989) antibodies from GeneTex (Irvine, CA), anti-SOD1 anti-
body (Cat. No. ab13498) from Abcam (Cambridge, UK), anti-CD3 (Cat. No. MAB4841),
anti-MGL1/2 (Cat. No. AF4297) and HRP -conjugated anti-goat IgG antibodies (Cat. No.
HAF017) from R&D systems (Minneapolis, MN), anti-MPO antibody from Proteintech
(Rosemont, IL; Cat. No. 66177-1-Ig), PE anti-mouse/human CD11b antibody (Cat. No.
101207) from Biolegend (San Diego, CA), vitality full length hrGFP polyclonal antibody (Cat.
No. 240141) from Agilent (Santa Clara, CA), HRP-conjugated anti-mouse IgG antibodies
(Cat. No. NA931), HRP-conjugated anti-rabbit IgG antibodies (Cat. No. NA934), HRP-conju-
gated anti-rat IgG antibodies (Cat. No. NA935) from GE Healthcare (Buckinghamshire, UK),
Alexa Fluor 596 donkey anti-mouse IgG antibody (Cat. No. A21203), Alexa Fluor 488 goat
anti-rabbit IgG antibody (Cat. No. A11008), Alexa Fluor 596 donkey anti-goat IgG antibody
(Cat. No. A11058), Texas Red-X goat anti-rat IgG antibody (Cat. No. T6392), and Alexa Fluor
647 goat anti-mouse antibody (Cat. No. A28181) from Invitrogen (Carlsbad, CA).
Virus preparation
IAV/PR8, IAV/Aichi, and IAV/WSN were grown in the allantoic sac of 11-day-old chicken
embryos (Ishii Co., Ltd.) at 36˚C for 48 hours. Eggs were chilled at 4˚C for at least 4 hours
prior to harvesting the allantoic fluids. Cellular debris was removed by centrifugation at
2,380×g at 4˚C for 30 min. The clarified supernatant was layered over a 20% sucrose cushion
and centrifuged at 25,000×g at 4˚C for 120 min. The virus pellet was suspended in phosphate-
buffered saline (PBS), and stored in multiple aliquots at -80˚C until use.
Intranasal infection of IAVs
After anesthesia with intramuscular injection of ketamine (Daiichi-Sankyo Propharma Co.,
LTD., Tokyo, Japan), male mice aged 5 weeks were intranasally inoculated with IAVs in a total
volume of 20 μL (10 μL in each nasal cavity), and monitored for survival, weight loss, and clini-
cal signs of illness for 14 days. The IAV stock aliquots were thawed and diluted in saline before
use. To remove tissues, mice were anesthetized with ketamine (Daiichi-Sankyo Propharma
Co., LTD.) and subjected to perfusion through the right ventricle with PBS.
Virus titer determination
Virus titers were expressed as IFU/mL, which was determined using Madin-Darby canine kid-
ney (MDCK) cells (kindly provided by Dr. Takaaki Nakaya, Kyoto Prefectural University of
Medicine) as follows. MDCK monolayer cells were inoculated with a 10-fold serial dilution of
each sample of interest for 14 hours at 37˚C. The cells were then fixed with 4% paraformalde-
hyde (PFA), permeabilized with 0.3% Triton-X100 in PBS, and immunostained with anti-NP
monoclonal antibodies (GeneTex). Signals were visualized using horseradish peroxidase
(HRP)-conjugated anti-rabbit IgG antibodies (GE Healthcare) and TrueBlue Peroxidase Sub-
strate (KPL, Gaithersburg, MD). IFU/mL was defined as the number of the cells positive for
the anti-NP signals in 1 mL of each sample.
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Antibody treatments
Mice were intraperitoneally injected with the indicated amounts of respective antibodies at
indicated times. Control mouse polyclonal IgG was purchased from Sigma-Aldrich (St Louis,
MO).
Purification of anti-PrP mAbs
38–2 [17], 3S9 [24,25], and 2H9 hybridoma cells [24,25] were inoculated into the peritoneal
cavity of BALB/cSlc-nu/nu mice (Japan SLC Inc.) pretreated with pristane (Sigma). Abs in
their ascites were then purified using a MAbTrap Kit (GE Healthcare) according to the manu-
facturers’ instructions.
Purification of 38–2 Fab
38–2 Fab and control mouse IgG Fab fragments were prepared using a Mouse IgG1 Fab and
F(ab’)2 Preparation Kit (Thermo Scientific Inc., Waltham, MA). In brief, 38–2 mAb and con-
trol mouse IgG (Sigma) were respectively subjected to proteolysis with immobilized ficin. The
digested Fc portion and undigested IgG fragment were removed by passing over a column of
immobilized protein A 3 times and the resulting elutes containing the Fab fragments was col-
lected. The Fab concentration was determined at 280 nm using a Nanodrop 1000 spectropho-
tometer (Thermo Scientific Inc.).
Oral administration with DS, PP2 and Imatinib
DS was purchased from Santa Cruz Biotechnology, PP2 from Tocris bioscience (Bristol UK),
and Imatinib mesylate from Selleck Chemicals (Houston, TX). DS and PP2 were dissolved in
dimethyl sulfoxide (DMSO) and stored at -20˚C. Imatinib mesylate was dissolved in water and
stored at -20˚C until use. DS was orally administered at 10 mg/kg/day or 20 mg/kg/day, and
PP2 was administered at 5 mg/kg/day using a sonde needle daily from -1 to 4 dpi. Imatinib
mesylate was orally administered at 200 mg/kg/day twice a day from -1 to 14 dpi.
Homogenization
Cells and tissues were homogenized in lysis buffer (0.5% Triton X-100, 0.5% Sodium deoxy-
cholate, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1 mM EDTA) containing protease inhibitor
cocktail (Nakalai Tesque, Kyoto, Japan) and phosphatase inhibitor cocktail (Nakalai Tesque).
The homogenate was centrifuged at 1,000×g at 4˚C. Protein concentration of the homogenates
was measured using the BCA method (Thermo Scientific Inc.).
Western blotting
Total proteins were denatured by boiling for 5 min in Laemmli’s sample buffer and subjected
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred onto
Immobilon-PVDF membranes (Millipore, Bedford, MA), and membranes were blocked for 2
hours with 5% non-fat dry milk-containing TBST (0.1% Tween-20, 100 mM NaCl, 10 mM
Tris-HCl, ph 7.6). Primary antibodies were incubated with the membrane overnight at 4˚C.
Signals were visualized using horseradish peroxidase-conjugated anti-mouse, anti-rabbit, anti-
goat, and anti-rat IgG antibodies (GE Healthcare), and detected using a chemiluminescence
image analyzer LAS-4000 mini (Fujifilm Co., Tokyo, Japan). Signal intensities were measured
using ImageJ 64 software (NIH, Bethesda, MD). The average and standard deviation (SD) of
the signals were calculated using Microsoft EXCEL software, version 16.37.
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Pathological examinations
Lung tissues were fixed with 4% PFA, dehydrated, embedded in paraffin, and cut into 5 μm-
thick tissue sections. The sections were deparaffinized and stained with hematoxylin-eosin
(H-E).
Determination of atelectatic lung areas
The atelectatic lung area was evaluated using Photoshop software (Adobe, San Jose, CA) and
ImageJ software (NIH, Bethesda, MD). Briefly, the original RGB color images of H-E stained
lung sections were converted to black-on-white images by use of Photoshop software and
saved in TIFF format. The binary images in TIFF format were again inverted into a white-on-
black image using the ImageJ application. Atelectatic lung area was expressed as the area of
white pixels, which represent the lung parenchyma, against total lung area (white and black
pixels).
Immunohistochemistry
Frozen 5 μm-thick tissue sections were fixed in cold acetone for 15 min, air-dried, and treated
for 30 min with a blocking reagent [10% fetal bovine serum (FBS) in PBS]. After washing with
PBS, the sections were incubated with primary antibodies overnight at 4˚C, and Alexa Fluor
488 goat anti-rabbit IgG (Invitrogen) for anti-NP and anti-pSFK (Tyr416) antibodies, Alexa
Fluor 594 donkey anti-goat IgG (Invitrogen) for anti-MGL1/2 antibody, Texas Red-X goat
anti-rat IgG (Invitrogen) for anti-CD3 antibody, and Alexa Fluor 594 donkey anti-rabbit IgG
(Invitrogen) for anti-MPO antibody for 2 hrs at room temperature (RT). The sections were
mounted with CC/Mount (Diagnostic BioSystems, Pleasanton, CA) containing DAPI
(Dojindo Laboratories, Kumamoto, Japan). Fluorescent images were visualized using BIOR-
EVO BZ-9000 (Keyence, Osaka, Japan).
Evaluation of NP-positive cells in the airway and parenchymal areas
Lung slices (n = 3 slices × 3 mice in each group) were stained with anti-NP antibody (Gene-
Tex). The NP-positive cells in large airway (larger than 100 μm diameter) was evaluated by
scoring 0 to 5 as followed: Score 0, intact epithelial cells in the airway without NP-positive
cells; score 1, intact epithelial cells in the airway with<50% NP-positive cells; score 2, intact
epithelial cells in the airway with>50% NP-positive cells; score 4,<50% epithelial cell injuries
in the airway with NP-positive cells; score 5,>50% epithelial cell injuries in the airway with
NP-positive cells. The NP positive cells in the parenchymal areas were counted using Photo-
shop software (Adobe) and ImageJ particle count command (NIH).
ELISA for cytokines
IL-6, IFN-γ, TNF-α, IL-4, and IL-10 levels in samples were determined using a Quantikine
ELISA kit (R&D systems, Minneapolis, MN) according to the respective protocols provided by
the manufacturer. In brief, the samples were diluted 1:1 with the assay diluent provided in the
kit and added to the ELISA microplate wells. The plates were then left for 2 hours at RT. The
wells were washed with the wash buffer 5 times and added with the mouse IFN-γ, TNF-α, IL-
4, and IL-10 conjugate for 2 hrs. The wells were then washed with the wash buffer and the sub-
strate reagent was added for 30 min. The reaction was stopped by addition of the stop solution.
The optical density of each well was measured at 450 nm in an automated microplate reader
(Thermo LabSystems, Waltham, MA).
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TUNEL staining
TUNEL staining was performed using the in situ cell death detection kit and fluorescein
(Roche Diagnostics, Mannheim, Germany) in accordance with the manufacturers’ protocol.
In brief, deparaffinized tissue sections were treated with 20 μg/mL proteinase K (Wako Pure
Chemical Industries) in 10 mM Tris-HCl for 30 min at RT and incubated in the TUNEL reac-
tion mixture for 1 hr at 37˚C in a humidified dark chamber. The sections were washed with
PBS for 5 min 3 times and signals were detected using BIOREVO BZ-9000 (Keyence).
RNA extraction and real-time RT-PCR
Total RNA was first extracted from cells and tissues using RNeasy Mini Kit (QIAGEN, Valen-
cia, CA). Homogenates in buffer RLT were transferred to a QIAshredder spin column (QIA-
GEN). The flow-through was mixed with 1 volume of 70% ethanol and then transferred to an
RNeasy spin column (QIAGEN). Total RNA bound to the membrane was washed with buffer
RW1 and then with buffer RPE, and eluted with RNase-free water. Total RNA was used in a
reverse transcription reaction using M-MLV Reverse Transcriptase (Promega, Madison, WI)
and real-time PCR was performed with FastStart Universal SYBR green PCR Master (Roche
Diagnostics) according to the manufacturers’ protocols. Optimal PCR conditions were 40
cycles of 3-step cycling (Denaturation at 95˚C for 15 sec, Annealing at 56˚C for 30 sec, Exten-
sion at 72˚C for 50 sec) after an initial denaturation step (95˚C for 10 min). For the relative
comparison of each gene expression, the data of real-time PCR were analyzed with 2-ΔCt
method. All real-time PCRs were run using the Applied Biosystems 7300 system (Foster City,
CA), and the cycle threshold (CT) value for each sample was obtained using ABI 7300 system
sequence detection software, version 1.3. Relative quantitative levels for each sample were cal-
culated on the basis of the CT value by standard curve methods and were normalized to
endogenous control β-actin expression. The normalized data of each gene were analyzed with
2-ΔCt method. The experiments were done in triplicate for each sample. Sequences of the prim-
ers used for each gene are given in S1 Table.
ROS measurement
ROS concentration in samples was measured using an OxiSelect Intracellular ROS Assay Kit
(Cell Biolabs, San Diego, CA). The assay uses 2’,7’-dichlorodihydrofluorescin diacetate
(DCFH-DA), which is deacetylated to non-fluorescent 2’,7’-dichlorodihydrofluorescin and
then oxidized by ROS to highly fluorescent 2’,7’-dichlorofluorescin (DCF). Each of the samples
were mixed with 1×DCFH-DA solution in a 96-well black plate and incubated at 37˚C for 48
hrs. ROS concentration in the samples was measured by determining the fluorescence intensi-
ties of DCF at 480 nm using Spectra Max Gemini EM (Molecular devices, Sunnyvale, CA).
Measurement of SOD activity
SOD activity in samples was determined using an OxiSelect Superoxide dismutase activity
assay kit (Cell Biolabs). This assay uses a xanthine/XO system to produce superoxide anions,
which reduce chromagen to produce a formazan dye, which is colorimetrically detectable at
490 nm. SOD activity in the samples was determined as the inhibition of formazan dye pro-
duction. Each of the samples was mixed with 1× XO solution in a 96-well black plate and incu-
bated at 37˚C for 60 min and the formazan dye produced was colorimetrically detected at 490
nm using Spectra Max Plus (Molecular devices).
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PM preparation
After anesthesia with intramuscular injection of ketamine (Daiichi-Sankyo Propharma Co.,
LTD.), PM was obtained by inoculating 10 mL of cold PBS into the abdominal cavity by using
26-gauge needles attached to a 20-mL syringe. After a soft massage of the abdomen for 30 sec-
onds, the peritoneal liquid was collected with 18-gauge needles attached to a 20-mL syringe.
This procedure was repeated 2 times for each animal. Total peritoneal liquids were centrifuged
at 300×g for 10 minutes to collect PM. The collected cells were adjusted to a concentration of
2.5×106 cells/mL in Dullbecco’s modified Eagle’s medium (DMEM, Wako Pure Chemicals)
supplemented with 10% FBS and cultured in a 96-well plate for 3 hrs. The cells were then cul-
tured in DMEM medium containing 1mg/mL of control IgG, 38–2, 3S9 or 2H9 mAb together
with DS or control DMSO for 3hrs before being subjected to Western blotting, ELISA, real-
time RT-PCR, FACS, and immunoprecipitation followed by mass spectrometry.
Alveolar macrophage preparation
Lungs were lavaged twice by injection with 2.0 ml of sterile saline using a syringe and the
lavaged fluids were harvested by gentle aspiration. The fluids were then centrifuged at 300×g
for 5 minutes to collect cells. The cells were adjusted to a concentration of 2.5×105 cells/mL in
DMEM supplemented with 10% FBS and cultured in a 96-well plate for 3hrs. The cells were
then treated with 1mg/mL of control IgG or 38–2 mAb in DMEM supplemented with 10%
FBS for 3hrs before being subjected to real-time RT-PCR.
Construction of pIRES-hrGFP-MoPrP
The DNA fragment encoding full-length mouse PrPC was amplified by PCR with a sense
primer (5’-tcggatcccgtcatcatggcgaac-3’; the underlined sequence, a BamH I site; the bold
sequence, a start codon) and an antisense primer (5’-ccctcgaggctcatcccacgatcaggaag-3’; the
underlined sequence, a Xho I site; the bold sequence, a stop codon) using pcDNA3.1/MoPrP
plasmid encoding mouse PrPC [44] as a template. After confirmation of the DNA sequences,
each DNA fragment was digested by BanH I and Xho I and introduced into a pIRES-hrGFP-
2a vector (Stratagene, La Jolla, CA).
Flow cytometry
N2aΔPrP cells [26] were plated onto 6-well plates on the day before transfection. pIRES-
hrGFP-MoPrP vector and control pIRES-hrGFP-2a vector (Stratagene) were transfected into
N2aΔPrP cells using Lipofectamone 2000 (Invitrogen) according to the manufacturers’
instructions. The cells were harvested 72 hrs after transfection using PBS containing 20 mM
EDTA and washed with FACS buffer (5% FBS in PBS). PM cells collected from the peritoneal
cavity were washed with PBS, incubated with ACK lysing buffer (150 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA) for 5 min to lyse red blood cells. The PM cells were then washed
again with PBS and incubated with FACS buffer containing Fc-blocker (Biolegend, San Diego,
CA; Cat. No. 101302) for 30 min on ice. Transfected N2aΔPrP and PM cells were incubated
with 4 μg/mL of control IgG (Sigma) or 38–2, 3S9, and 2H9 anti-PrP mAbs in the FACS buffer
for 1 hr on ice. For PM cells, we also used PE anti-mouse/human CD11b antibody (Biolegend).
The cells were washed with the FACS buffer 3 times to remove unbound antibodies, incubated
with 1:800 diluted Alexa Fluor 647 anti-mouse antibody (Invitrogen), washed with PBS 3
times, suspended in PBS containing 10 mM EDTA and 0.2% bovine serum albumin, and ana-
lyzed using a CytoFLEX Flow Cytometer with CytExpert software, version 2.3 (Beckman
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Coulter, Inc., Brea, CA). Data were analyzed using FlowJo software, version 10.6.2 (Treestar
Unc., Ashland, OR).
Mass spectrometry analysis
PM were treated for 3 hrs in DMEM medium containing 1 mg/mL of control IgG or 38–2 mAb
as described above, followed by two washes with ice-cold PBS. Cells were lysed in RIPA lysis
buffer (1% NP-40, 0.25% Sodium deoxycholate, 0.05% SDS, 150 mM NaCl, 20 mM HEPES-
NaOH, pH 7.5, 1 mM EGTA, and 1 mM MgCl2) containing Complete protease inhibitors
(Merck Millipore, Darmstadt, Germany), PhosSTOP phosphatase inhibitors (Merck Millipore),
and 50 units/ml of benzonase endonuclease(Merck Millipore) on ice for 10 min. After centrifu-
gation at 20,000×g for 15 min at 4˚C, the supernatants were incubated with anti-phosphorylated
SFK (Tyr416) antibody (Cell Signaling Technology) that was immobilized on SureBeads Protein
G magnetic beads (Bio-Rad, Hercules, CA) for 3 hrs at 4˚C with rotation. The beads were
washed four times with RIPA buffer and then with 50 mM ammonium bicarbonate twice. Pro-
teins on the beads were digested with 200 ng trypsin/Lys-C mix (Promega) for 16 hrs at 37˚C.
The digests were reduced, alkylated, acidified, and desalted using GL-Tip SDS (GL Sciences,
Tokyo, Japan). The eluates were evaporated and dissolved in 3% acetonitrile (ACN) and 0.1%
trifluoroacetic acid. LC-MS/MS analysis of the resultant peptides was performed on an EASY-
nLC 1200 UHPLC (Thermo Fisher Scientific) connected to an Orbitrap Fusion mass spectrom-
eter (Thermo Fisher Scientific) equipped with a nanoelectrospray ion source (Thermo Fisher
Scientific). The peptides were separated on a 75 μm inner diameter ×150 mm C18 reversed-
phase column (Nikkyo Technos, Tokyo, Japan) with a linear 4–32% ACN gradient for 0–100
min followed by an increase to 80% ACN for 10 min. The mass spectrometer was operated in a
data-dependent acquisition mode with a maximum duty cycle of 3 sec. MS1 spectra were mea-
sured with a resolution of 120,000 and a mass range from 375 to 1,500 m/z. HCD MS/MS spec-
tra were acquired in the linear ion trap with an isolation window of 1.6 m/z and a normalized
collision energy of 30. Dynamic exclusion was set to 15 sec. Raw data were directly analyzed
against the SwissProt database restricted to M. musculus using Proteome Discoverer version 2.4
(Thermo Fisher Scientific) with Mascot search engine version 2.5 (Matrix Science, London,
UK). The search parameters were as follows: (i) trypsin as an enzyme with up to two missed
cleavages; (ii) precursor mass tolerance of 10 ppm; (iii) fragment mass tolerance of 0.6 Da; (iv)
carbamidomethylation of cysteine as a fixed modification; and (v) acetylation of the protein N-
terminus and oxidation of methionine as variable modifications. Peptides and proteins were fil-
tered at a false-discovery rate (FDR) of 1% using the percolator node and the protein FDR vali-
dator node, respectively. Label-free precursor ion quantification was performed using the
precursor ions quantifier node, and normalization was performed such that the total sum of
abundance values for each sample over all peptides was the same. The abundance for each pro-
tein was analyzed using Proteome Discoverer version 2.4 (Thermo Fisher Scientific).
Statistical analysis
Survival rates were analyzed using the log-rank (Mantel-Cox) test (GraphPad Prism software
package version 5.04). All other statistical analysis data were determined using a Student’s t-
test (Microsoft EXCEL software, version 16.37).
Supporting information
S1 Table. List of primers used in RT-PCR with their DNA sequences and the number of
PCR cycles.
(DOCX)
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S1 Fig. 38–2 mAb protects against lethal infection with IAV/PR8 in mice. The survival rate
(%, upper panel) and body weight loss (%, lower panel) of WT mice intraperitoneally adminis-
tered with either the buffer alone (0 mg/mouse) and 0.2 mg/mouse and 0.5 mg/mouse of 38–2
mAb 1 day before intranasal infection with 200 IFU of IAV/PR8. Error bars, standard devia-
tions (SD). �, p<0.05.
(TIF)
S2 Fig. 38–2 mAb suppresses lung exudates in mice infected with IAV/PR8. Wet lung/
body weight (%) in mice treated control IgG- and 38–2 mAb at 0 (uninfected), 3, 5, and 8 dpi
with 200 IFU of IAV/PR8. ��, p<0.01.
(TIF)
S3 Fig. 38–2 mAb suppresses lung epithelial cell apoptosis in mice infected with IAV/PR8.
Western blotting for the AT1 cell marker podoplanin, the AT2 cell marker SP-C, the Clara cell
marker CC10, pro-caspase 3, and the cleaved caspase 3 in lungs from control IgG- and 38–2
mAb-treated mice uninfected and at 3 and 5 dpi with 200 IFU of IAV/PR8. Signal densities of
these molecules were combined with those in Fig 2D to statistically quantify the densities of
each molecule. Actb, β-actin.
(TIF)
S4 Fig. 38–2 mAb suppresses apoptosis in the lungs of mice infected with IAV/PR8.
TUNEL staining of the lungs from control IgG- and 38–2 mAb-treated mice uninfected and at
3 and 5 dpi with 200 IFU of IAV/PR8. Bar, 0.5 mm.
(TIF)
S5 Fig. DS abolishes the protective activity of 38–2 mAb in mice infected with IAV/PR8.
The survival rate (%, upper panels) and body weight loss (%, lower panels) of WT mice intra-
peritoneally administrated with control IgG (left panels) and 38–2 mAb (right panel) together
with 10 mg of DS 1 day before intranasal infection with 200 IFU of IAV/PR8. Error bars, SD. �,
p<0.05.
(TIF)
S6 Fig. PP2 but not imatinib abolishes the protective activity of 38–2 mAb in mice infected
with IAV/PR8. The survival rate (%, upper panels) and body weight loss (%, lower panels) of
WT mice intraperitoneally administrated with control IgG (left panels) and 38–2 mAb (right
panel) together with 5 mg of PP2 (A) or 200 mg of imatinib (B) 1 day before intranasal infec-
tion with 200 IFU of IAV/PR8. Error bars, SD. �, p<0.05; ��, p<0.01.
(TIF)
S7 Fig. 38–2 mAb polarizes alveolar macrophages to a M2 phenoptype. Real-time PCR for
M1-specific genes (TNF-α and INF-γ) and M2-specific genes (MGL1 and IL-10) in alveolar
macrophages collected from the BALFs of WT mice 3 hrs after treatment with control IgG and
38–2 mAb (n = 3 in each group). ��, p<0.01.
(TIF)
S8 Fig. 38–2 mAb increased phosphorylated Lyn (Tyr416) and, to a lesser extent, phos-
phorylated Hck (Tyr416) in peritoneal macrophages. The abundance of each SFK in the
immunoprecipitate with anti-phosphorylated SFK (Tyr416) Ab in peritoneal macrophages 3
hrs after treatment with control IgG and 38–2 mAb.
(TIF)
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S9 Fig. Therapeutic effects of 38–2 mAb against lethal infection with IAV/PR8. The sur-
vival rate (%, upper panel) and body weight loss (%, lower panel) of WT mice intraperitoneally
administered with 38–2 mAb 5 days after intranasal infection with 200 IFU of IAV/PR8. Con-
trol IgG was similarly injected into WT mice 3 days after infection with 200 IFU of IAV/PR8.
Error bars, SD.
(TIF)
S10 Fig. 38–2, 3S9, 2H9 mAbs recognize PrPC on Western blotting. Uncropped, full picture
of Western blotting for PrPC with 38–2, 3S9, 2H9 mAbs in the brains (Br) and lungs (Lg) from
WT and Prnp0/0 mice in Fig 10A.
(TIF)
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